Generic drug maker Myan said Thursday that its upcoming merger with Upjohn likely would be delayed until the second half of this year because of expected delays in the regulatory approval process due to the pandemic.

Previously, the merger was expected to be completed by mid-2020.

Mylan, which is incorporated in the Netherlands and is run from executive offices in Cecil, said there were no changes to the previously announced terms of the deal.

Upjohn, based in China, is the generic and off-patent brand name drug unit of Pfizer Inc.

Advertise with us

The newly combined company is to be called Viatris.

Mylan also said that a special meeting in the Netherlands to approve certain matters related to the transaction was being rescheduled from April 17 to June 30. The company’s annual meeting also will be held that day in the Netherlands.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.